Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Non invasive Cell Based Liquid Biopsy Platform for Bladder Cancer

Funder: European Commission

Funding period
EUR 3.7 M
USD 4.2 M
Funding amount
OneRNA4Bladder aims to save lives and reduce cost of care for bladder cancer treatment – the most expensive type of cancer to treat due to expensive diagnostic procedures and ineffective drugs leading to a recurrence rate of 70%. Implementing the OneRNA4Bladder system for bladder cancer recurrence detection could cut the cost of managing bladder cancer in half, resulting in savings of more than €800 million/year in Europe

The key project technology is a patented Urine Cancer Cell Filtration Device (UCCFD) that enables the selection of tumor cells from a simple urine sample. The UCCFD was developed and validated in a small prospective clinical study by the Danish Cancer Society and in-licensed by Genomic Expression Aps (GEx). In OneRNA4Bladder, GEx aims at the clinical validation of the UCCFD – in combination with DNA biomarkers – for the detection of bladder cancer recurrence. Furthermore, the UCCFD can – in combination with GEx’s proprietary OneRNA™ platform, which links RNA's to drugs that can provide a more effective treatment – be applied as a liquid biopsy platform to monitor the disease response to treatment without invasive biopsies or cystoscopies. In OneRNA4Bladder, we will also clinically validate the UCCFD technology together with OneRNA™ as a liquid biopsy platform.

OneRNA4Bladder is an opportunity for GEx to enter the world-wide bladder cancer diagnostic market. The accomplishment of the project objectives will represent a significant business opportunity for the SME, with expected sales of over €165 million within 5 years of launch.
Similar projects All >
Sorted by: Start Date
Project list item
Improved detection of bladder cancer recurrence using a biophysical biomarker

National Cancer Institute to MICHAEL D HENRY

USD 301,860
2017 - 2020
Project list item
Multi-modal, Endoscopic Biophotonic Imaging of Bladder Cancer for Point-of-Care Diagnosis

European Commission

USD 6,760,912
2016 - 2020
Project list item
Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers

Congressionally Directed Medical Research Programs to Kelly Standifer

USD 592,000
2015 - 2016
Project list item
Synergistic Immuno-Photo-Nanotherapy for Bladder Cancer

Congressionally Directed Medical Research Programs to Brant A. Inman

USD 624,398
2015 - 2016
Project list item
Development of the UroMark assay. A non-invasive test for the detection of bladder cancer in urinary sediment cells

Medical Research Council to John Kelly, Stephan Beck, Norman R Williams, Andrew Feber, Chris Brew-Graves, Martin Anyim

USD 2,181,832
2015 - 2020



    0903 Biomedical Engineering


    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC

    Urologic Diseases




    4.1 Discovery and preclinical testing of markers and technologies


    4.2 Evaluation of markers and technologies

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science